N/A N=1,097 Prenatal Genetic Diagnosis by Genomic Sequencing
Fetal Structural Anomalies
Primary: Number of Participants Who Had Reportable Variants — 114; 22 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=81 Safety and Effectiveness Evaluation of Peripheral Orbital Atherectomy
Peripheral Artery Disease
Primary: Percentage of Subjects With Acute Device Success — 55 Participants
N/A N=90 Health, Aging and Later-Life Outcomes
Aging
Primary: Number of Participants That Sustained >10% Caloric Restriction — 7; 12 Participants
N/A N=28 Addressing Disparities in Neuromodulation for Rehabilitation: A Mixed Methods Approach to Optimize Access for Underrepresented Racial Minorities
Neuropathic Pain
Primary: Change Expectation for Pain Relief as Measured by EXPECT Scores — 0.19; 0.28 score on a scale
Phase 2 N=10 Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx)
CNS Germ Cell Tumor
Primary: Response Rate — 0; 0; 4; 2 Participants
Phase 2 N=60 Intermittent Oral Naltrexone Enhanced With an Ecological Momentary Intervention for Methamphetamine-using MSM
Methamphetamine Use Disorder
Primary: Number of People With Meth-positive Urine Tests at Weekly Visits — 20; 13; 23; 9 Participants
N/A N=12 Analysis and Suppression of Tremor During Grasp Using Ultrasound Imaging and Electrical Stimulation
Parkinson Disease · Essential Tremor
Primary: Tremor Model Accuracy — 24; 21 Normalized RMSE (%)
N/A N=15 Does Adding a Tailored Cognitive Behavioral Therapy (CBT) Mobile Skills App Mediate Rates of Depression
Depression
Primary: Skills of Cognitive Therapy (Patient Version) — 24.231; 24.231 units on a scale
N/A N=1,494 Introducing Palliative Care (PC) Within the Treatment of End Stage Liver Disease (ESLD)
End Stage Liver Disease · Decompensated Cirrhosis of Liver
Primary: Quality of Life (QOL) — 7.02; 8.01 score on a scale
Phase 3 N=62 Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-1)
Bronchiolitis Obliterans · Chronic Rejection of Lung Transplant · Lung Transplant Rejection
Primary: Mean Change in FEV1 (L) From Baseline to Week 48 — -0.186; -0.090 liters — p=0.7310
Phase 4 N=52 Tobacco Treatment Comparison for Cancer Care
Smoking Cessation · Cancer
Primary: Biochemically Verified 7-day Point-prevalence Abstinence 26 Weeks After a Target Quit Date. — 2; 7 Participants
Phase 4 N=100 Suvorexant and Sleep/Delirium in ICU Patients
Insomnia · Sleep Fragmentation · Sleep Initiation and Maintenance Disorders
Primary: Nighttime Wakefulness After Persistent Sleep Onset (WASO) — 200.7; 184.2 minutes
Phase 3 N=54 The Women TAF-FTC Benchmark Study
HIV Infections
Primary: Frequency of Adverse Events — 69; 60; 62; 1 Number of adverse events
N/A N=200 Regent China Post-Market Clinical Follow-up Study
Valvular Heart Disease · Aortic Valve Disease
Primary: Primary Safety Endpoint: The Freedom From Valve-related Mortality — 98.4 percentage of participants
N/A N=100 Point-of-care Urine Monitoring of Adherence: Testing a Real-Time Urine Assay of Tenofovir in PrEP
Risk Reduction
Primary: Long-term Adherence Metrics Via Hair Concentrations of Tenofovir and Short-term Adherence Metric of Urine Concentrations of Tenofovir. — 33; 26; 31; 19 Participants